Skip to content

Study · Non-randomized trial · 2013

4 results

Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome.

Tappenden KA, Edelman J, Joelsson B

Journal of clinical gastroenterology1 Aug 2013Cited by 51 (Europe PMC)

PMID23426461 (opens in a new tab)DOI10.1097/mcg.0b013e3182828f57 (opens in a new tab)PepBankPUB-23426461
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In SBS-IF patients in the teduglutide arm reported as 0.5 or 0.05 mg/kg/d, no intestinal biopsy showed dysplasia after 6 months.

    In plain wordsIn SBS-IF patients, no intestinal biopsy showed dysplasia after six months in the teduglutide arm with inconsistent dose reporting.

    Peptide
    Teduglutide
    Outcome
    Not applicableDysplasia in dose-inconsistent teduglutide arm
    Study

    n: not reported in source

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    After 6 months of treatment, no features of dysplasia were found in any biopsy from the large or small intestine of patients receiving placebo or either dose of teduglutide.
    3 context sentences
    Summary · context
    In a multicenter, prospective, randomized, placebo-controlled study, 83 PN-dependent patients with SBS-IF were monitored for several weeks to ensure optimal and stable PN.
    Summary · context
    Patients were then randomized to receive 24 weeks of placebo (n=16), teduglutide (0.5 mg/kg/d; n=35), or teduglutide (0.10 mg/kg/d; n=32).
    Summary · context
    Biopsies were obtained from 77 patients to yield 390 individual histologic interpretations.
  2. 02HumanNon-randomized trialSafety outcome

    In SBS-IF patients receiving teduglutide 0.10 mg/kg/d, no large- or small-intestinal biopsy showed dysplasia after 6 months.

    In plain wordsIn SBS-IF patients receiving teduglutide 0.10 mg/kg/d, no intestinal biopsy showed dysplasia after six months.

    Peptide
    Teduglutide
    Outcome
    Not applicableDysplasia in 0.10 mg/kg/d arm
    Study

    n: not reported in source

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.10 mg/kg/d · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    After 6 months of treatment, no features of dysplasia were found in any biopsy from the large or small intestine of patients receiving placebo or either dose of teduglutide.
    3 context sentences
    Summary · context
    In a multicenter, prospective, randomized, placebo-controlled study, 83 PN-dependent patients with SBS-IF were monitored for several weeks to ensure optimal and stable PN.
    Summary · context
    Patients were then randomized to receive 24 weeks of placebo (n=16), teduglutide (0.5 mg/kg/d; n=35), or teduglutide (0.10 mg/kg/d; n=32).
    Summary · context
    Biopsies were obtained from 77 patients to yield 390 individual histologic interpretations.
  3. 03HumanNon-randomized trialSafety outcome

    In SBS-IF patients receiving teduglutide 0.05 mg/kg/d, new secondary diagnoses such as eosinophilic colitis or Crohn's disease occurred at frequencies of 3.1% to 6.3%.

    In plain wordsIn SBS-IF patients receiving teduglutide reported as 0.05 mg/kg/d, new intestinal diagnoses occurred at frequencies of 3.1% to 6.3%.

    Peptide
    Teduglutide
    Outcome
    Not applicableNew secondary histologic diagnoses at 0.05 mg/kg/d
    Study

    n: not reported in source

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.05 mg/kg/d · 24 weeksAs given in this study (human).

    Measurements

    New secondary diagnoses frequency
    3.1 to 6.3%
    teduglutide 0.05 mg/kg/d

    Source sentences

    Summary
    New secondary diagnoses, such as eosinophilic colitis or Crohn's disease, were found at a low frequency overall: teduglutide (0.05 mg/kg/d; range, 3.1% to 6.3%); teduglutide (0.10 mg/kg/d, 3.3%); placebo (range, 6.7% to 13.3%).
    3 context sentences
    Summary · context
    In a multicenter, prospective, randomized, placebo-controlled study, 83 PN-dependent patients with SBS-IF were monitored for several weeks to ensure optimal and stable PN.
    Summary · context
    Patients were then randomized to receive 24 weeks of placebo (n=16), teduglutide (0.5 mg/kg/d; n=35), or teduglutide (0.10 mg/kg/d; n=32).
    Summary · context
    Biopsies were obtained from 77 patients to yield 390 individual histologic interpretations.
  4. 04HumanNon-randomized trialSafety outcome

    In SBS-IF patients receiving teduglutide 0.10 mg/kg/d, new secondary diagnoses such as eosinophilic colitis or Crohn's disease occurred at a frequency of 3.3%.

    In plain wordsIn SBS-IF patients receiving teduglutide 0.10 mg/kg/d, new secondary intestinal diagnoses occurred at a frequency of 3.3%.

    Peptide
    Teduglutide
    Outcome
    Not applicableNew secondary histologic diagnoses at 0.10 mg/kg/d
    Study

    n: not reported in source

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.10 mg/kg/d · 24 weeksAs given in this study (human).

    Measurements

    New secondary diagnoses frequency
    3.3%
    teduglutide 0.10 mg/kg/d

    Source sentences

    Summary
    New secondary diagnoses, such as eosinophilic colitis or Crohn's disease, were found at a low frequency overall: teduglutide (0.05 mg/kg/d; range, 3.1% to 6.3%); teduglutide (0.10 mg/kg/d, 3.3%); placebo (range, 6.7% to 13.3%).
    3 context sentences
    Summary · context
    In a multicenter, prospective, randomized, placebo-controlled study, 83 PN-dependent patients with SBS-IF were monitored for several weeks to ensure optimal and stable PN.
    Summary · context
    Patients were then randomized to receive 24 weeks of placebo (n=16), teduglutide (0.5 mg/kg/d; n=35), or teduglutide (0.10 mg/kg/d; n=32).
    Summary · context
    Biopsies were obtained from 77 patients to yield 390 individual histologic interpretations.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.